BluePrint
BluePrint,* a molecular subtyping test, analyzes the activity of 80 genes to enable stratification of the tumor into one of the three following subtypes: Luminal-type, HER2-type† and Basal-type.‡ By combining MammaPrint and BluePrint, patients can be stratified into the following four subgroups: Luminal-type/MammaPrint Low Risk (Luminal A§); Luminal-type/MammaPrint High Risk (Luminal B||); HER2-type and Basal-type patients.1
Each breast cancer subtype is markedly different in its degree of aggressiveness, long-term outcome, and response to chemotherapy. With subtype information, provided by BluePrint in combination with MammaPrint, physicians are better informed to make decisions about a patient’s specific options, thereby personalizing her treatment.
In a 2013 study2 adding BluePrint molecular subtyping to MammaPrint helped to better predict a patient’s prognosis and aid in the choice of therapy, versus traditional methods like IHC and FISH.
21% of patients were reclassified as MammaPrint Low Risk, BluePrint Luminal-Type A and showed little, if any, benefit from chemotherapy.2
REFERENCES
1Glück S, de Snoo F, Peeters J, Stork-Sloots L, Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013; 139(3):759-67
2Krijgsman O, Roepman P, Zwart W, et al. A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response. Breast Cancer Res Treat. 2012; 133:37-47